Q4FY26 and FY26 saw robust growth in sales, EBITDA, and profitability, with strong performances across HPP, Specialty Chemicals, and CDMO. Ongoing capex and R&D investments support future growth, while ESG initiatives and strong governance underpin sustainable progress.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.